In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NxStage clears US hurdle in Medisystems acquisition:

This article was originally published in Clinica

Executive Summary

US antitrust authorities have completed a review of NxStage Medical's proposed buyout of its long-term business partner Medisystems Corporation, bringing NxStage closer to purchasing the developer of disposables used in dialysis and blood treatment. The firm says it has begun to implement organisational changes in anticipation of the transaction, expected to close during the fourth quarter of 2007. Lawrence, Massachusetts-based NxStage has promoted that Michael Webb to the newly-created position of senior vice-president of quality, regulatory and clinical affairs, whereas, upon the closing of the deal, Phil Licari will resign as senior vice-president and chief operating officer to pursue other opportunities. The deal, signed in June, is valued at around $78.7m (see Clinica No 1259, p 18).

You may also be interested in...

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies

US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts